Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer. In all, 38 patients with metastatic colorectal cancer were treated with erlotinib at a co...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Townsley, C A, Major, P, Siu, L L, Dancey, J, Chen, E, Pond, G R, Nicklee, T, Ho, J, Hedley, D, Tsao, M, Moore, M J, Oza, A M
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2006
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361254/
https://ncbi.nlm.nih.gov/pubmed/16570047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603055
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares